SG10202111399YA - Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers - Google Patents

Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Info

Publication number: SG10202111399YA
Authority: SG; Singapore
Prior art keywords: peptides; cancers; combination; breast cancer; against breast
Prior art date: 2015-12-22

Application number

SG10202111399YA

Inventor

Andrea Mahr

Toni Weinschenk

Helen Hörzer

Oliver Schoor

Jens Fritsche

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-22

Filing date

2016-11-29

Publication date

2021-11-29

2015-12-22 Priority claimed from GBGB1522667.3A external-priority patent/GB201522667D0/en

2016-11-29 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2021-11-29 Publication of SG10202111399YA publication Critical patent/SG10202111399YA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Endocrinology (AREA)
Marine Sciences & Fisheries (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)

SG10202111399YA 2015-12-22 2016-11-29 Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers SG10202111399YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562270968P	2015-12-22	2015-12-22
GBGB1522667.3A GB201522667D0 (en)	2015-12-22	2015-12-22	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Publications (1)

Publication Number	Publication Date
SG10202111399YA true SG10202111399YA (en)	2021-11-29

Family

ID=63849964

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10202111399YA SG10202111399YA (en)	2015-12-22	2016-11-29	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Country Status (9)

Country	Link
US (12)	US10143733B2 (en)
CL (6)	CL2018001531A1 (en)
CY (1)	CY1124224T1 (en)
HR (1)	HRP20210698T1 (en)
IL (1)	IL258599A (en)
PH (1)	PH12018500864A1 (en)
SG (1)	SG10202111399YA (en)
TW (3)	TWI720424B (en)
ZA (1)	ZA201801036B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102383710B1 (en) *	2013-08-05	2022-04-08	이매틱스 바이오테크놀로지스 게엠베하	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
ES2928164T3 (en)	2015-10-19	2022-11-15	Incyte Corp	Heterocyclic compounds as immunomodulators
ES2928856T3 (en)	2015-11-19	2022-11-23	Incyte Corp	Heterocyclic compounds as immunomodulators
TW201726623A (en)	2015-12-17	2017-08-01	英塞特公司	Heterocyclic compound as an immunomodulator
SG10202111399YA (en)	2015-12-22	2021-11-29	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
EP3394033B1 (en)	2015-12-22	2020-11-25	Incyte Corporation	Heterocyclic compounds as immunomodulators
ES2906460T3 (en)	2016-05-06	2022-04-18	Incyte Corp	Heterocyclic compounds as immunomodulators
EP3464279B1 (en)	2016-05-26	2021-11-24	Incyte Corporation	Heterocyclic compounds as immunomodulators
CA3028685A1 (en)	2016-06-20	2017-12-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018013789A1 (en)	2016-07-14	2018-01-18	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018044783A1 (en)	2016-08-29	2018-03-08	Incyte Corporation	Heterocyclic compounds as immunomodulators
MX391980B (en)	2016-12-22	2025-03-21	Incyte Corp	TETRAHYDROIMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS INDUCERS OF PROGRAMMED DEATH LIGAND 1 (PD-L1) INTERNALIZATION.
ES2874756T3 (en)	2016-12-22	2021-11-05	Incyte Corp	Triazolo [1,5-A] pyridine derivatives as immunomodulators
PE20191532A1 (en)	2016-12-22	2019-10-23	Incyte Corp	HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EP3558973B1 (en)	2016-12-22	2021-09-15	Incyte Corporation	Pyridine derivatives as immunomodulators
TW201835049A (en)	2016-12-22	2018-10-01	美商英塞特公司	Heterocyclic compounds as immunomodulators
IL313101A (en)	2018-03-30	2024-07-01	Incyte Corp	Heterocyclic compounds as immunomodulators
MD3790877T2 (en)	2018-05-11	2023-08-31	Incyte Corp	Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
TW202115059A (en)	2019-08-09	2021-04-16	美商英塞特公司	Salts of a pd-1/pd-l1 inhibitor
JP7559059B2 (en)	2019-09-30	2024-10-01	インサイト・コーポレイション	Pyrido[3,2-D]pyrimidine compounds as immunomodulators - Patents.com
WO2021096849A1 (en)	2019-11-11	2021-05-20	Incyte Corporation	Salts and crystalline forms of a pd-1/pd-l1 inhibitor
TW202233615A (en)	2020-11-06	2022-09-01	美商英塞特公司	Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en)	2020-11-06	2023-10-10	Incyte Corporation	Process of preparing a PD-1/PD-L1 inhibitor
JP2023548859A (en)	2020-11-06	2023-11-21	インサイト・コーポレイション	Process for making PD-1/PD-L1 inhibitors and their salts and crystalline forms
US20250381248A1 (en) *	2022-06-30	2025-12-18	Lonza Sales Ag	Methods of treating a tumor
CN116042823B (en) *	2022-09-19	2024-03-29	广东省人民医院	Molecular markers and their applications for assessment of prognosis and therapeutic efficacy of esophageal squamous cell carcinoma
TWI808897B (en) *	2022-09-28	2023-07-11	鈺邦科技股份有限公司	Wound capacitor package structure and method of manufactured the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9805877D0 (en) *	1998-03-20	1998-05-13	Imp Cancer Res Tech	Cancer
CA2380873A1 (en)	1999-06-30	2001-01-04	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en)	1999-06-30	2003-11-13	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US7211649B1 (en) *	1999-07-02	2007-05-01	Ana Mar Medical Ab	Cartilage intermediate layer protein
EP1690872A3 (en)	1999-12-01	2006-08-23	Genentech, Inc.	Composition and methods for the diagnosis of tumours
CA2393730A1 (en)	1999-12-13	2001-06-14	Epimmune Inc.	Hla class i a2 tumor associated antigen peptides and vaccine compositions
JP4900884B2 (en)	2000-07-31	2012-03-21	株式会社グリーンペプタイド	Tumor antigen
WO2002016939A2 (en)	2000-08-18	2002-02-28	Eos Biotechnology, Inc.	Methods of diagnosis of cancer and screening for cancer modulators
US7919467B2 (en)	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6535424B2 (en) *	2001-07-25	2003-03-18	Advanced Micro Devices, Inc.	Voltage boost circuit using supply voltage detection to compensate for supply voltage variations in read mode voltage
DE10225144A1 (en)	2002-05-29	2003-12-18	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding to MHC molecules
WO2005007090A2 (en) *	2003-07-03	2005-01-27	President And Fellows Of Harvard College	Inhibitors of the map kinase pathway
WO2006010051A2 (en)	2004-07-07	2006-01-26	Metabolex, Inc.	Methods of diagnosing & treating diabetes and insulin resistance
FR2894985B1 (en)	2005-12-20	2008-01-18	Alcan Rhenalu Sa	HIGH-TENACITY ALUMINUM-COPPER-LITHIUM PLASTER FOR AIRCRAFT FUSELAGE
WO2008016356A2 (en)	2006-08-02	2008-02-07	Genizon Biosciences	Genemap of the human genes associated with psoriasis
EP2215108A4 (en)	2007-10-23	2012-07-04	Univ Colorado	COMPETITIVE INHIBITORS OF EXPRESSION OF INVARIANT CHAINS AND / OR BINDING OF AN ECTOPIC CLIP
KR100999043B1 (en)	2007-12-04	2010-12-09	한국생명공학연구원	Mass production method of active domain of human protein tyrosine dephosphatase without fusion protein
SI2119726T2 (en)	2008-05-14	2018-03-30	Immatics Biotechnologies Gmbh	Novel and powerful MHC-class II peptides derived from survivin and neurocan
WO2011119484A1 (en)	2010-03-23	2011-09-29	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
WO2012127023A1 (en)	2011-03-23	2012-09-27	Detica Patent Limited	An automated fraud detection method and system
EP2771349B1 (en)	2011-09-16	2020-02-26	Iogenetics, LLC.	Bioinformatic processes for determination of peptide binding
EP2872530A4 (en)	2012-07-10	2016-04-06	Oncotherapy Science Inc	Kif20a epitope peptides for th1 cells and vaccines containing the same
GB201214007D0 (en) *	2012-08-07	2012-09-19	Scancell Ltd	Anti-tumour immune responses to modified self-epitopes
TWI775117B (en)	2013-08-05	2022-08-21	德商伊瑪提克斯生物科技有限公司	Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
SG10202111399YA (en)	2015-12-22	2021-11-29	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

2016
- 2016-11-29 SG SG10202111399YA patent/SG10202111399YA/en unknown
- 2016-11-29 HR HRP20210698TT patent/HRP20210698T1/en unknown
- 2016-12-22 TW TW108105097A patent/TWI720424B/en not_active IP Right Cessation
- 2016-12-22 TW TW111119458A patent/TW202241939A/en unknown
- 2016-12-22 TW TW109134386A patent/TWI768491B/en not_active IP Right Cessation
2018
- 2018-02-15 ZA ZA2018/01036A patent/ZA201801036B/en unknown
- 2018-04-10 IL IL258599A patent/IL258599A/en unknown
- 2018-04-23 PH PH12018500864A patent/PH12018500864A1/en unknown
- 2018-06-08 CL CL2018001531A patent/CL2018001531A1/en unknown
- 2018-06-29 US US16/024,142 patent/US10143733B2/en active Active
- 2018-06-29 US US16/024,133 patent/US10143732B2/en active Active
- 2018-06-29 US US16/024,164 patent/US10166278B2/en active Active
- 2018-11-01 US US16/177,919 patent/US10238728B2/en active Active
- 2018-12-05 US US16/210,357 patent/US10376569B2/en active Active
2019
- 2019-06-28 US US16/456,815 patent/US10485859B2/en active Active
- 2019-09-25 US US16/582,096 patent/US10596243B2/en active Active
- 2019-10-16 CL CL2019002941A patent/CL2019002941A1/en unknown
- 2019-10-16 CL CL2019002939A patent/CL2019002939A1/en unknown
- 2019-10-16 CL CL2019002940A patent/CL2019002940A1/en unknown
2020
- 2020-01-24 US US16/752,156 patent/US10675338B1/en not_active Expired - Fee Related
- 2020-05-01 US US16/864,558 patent/US11065314B2/en not_active Expired - Fee Related
2021
- 2021-05-28 US US17/333,902 patent/US12226466B2/en active Active
- 2021-06-10 CY CY20211100515T patent/CY1124224T1/en unknown
- 2021-09-29 CL CL2021002525A patent/CL2021002525A1/en unknown
- 2021-09-29 CL CL2021002524A patent/CL2021002524A1/en unknown
2022
- 2022-09-16 US US17/932,836 patent/US20230101093A1/en not_active Abandoned
2025
- 2025-01-10 US US19/016,817 patent/US20250144192A1/en active Pending

Also Published As

Publication number	Publication date
CL2021002524A1 (en)	2022-07-08
US20200009237A1 (en)	2020-01-09
TWI720424B (en)	2021-03-01
US10143733B2 (en)	2018-12-04
TWI768491B (en)	2022-06-21
TW202110876A (en)	2021-03-16
CL2019002941A1 (en)	2020-03-13
US20180303921A1 (en)	2018-10-25
US20200268863A1 (en)	2020-08-27
CL2019002939A1 (en)	2020-03-13
US10596243B2 (en)	2020-03-24
US11065314B2 (en)	2021-07-20
US20200164053A1 (en)	2020-05-28
US20190328856A1 (en)	2019-10-31
US20250144192A1 (en)	2025-05-08
US10485859B2 (en)	2019-11-26
US20190091312A1 (en)	2019-03-28
US20210290743A1 (en)	2021-09-23
CL2021002525A1 (en)	2022-07-08
CL2019002940A1 (en)	2020-03-13
TW201930348A (en)	2019-08-01
US10166278B2 (en)	2019-01-01
US10376569B2 (en)	2019-08-13
HRP20210698T1 (en)	2021-09-17
CY1124224T1 (en)	2022-05-27
US20230101093A1 (en)	2023-03-30
US10238728B2 (en)	2019-03-26
TW202241939A (en)	2022-11-01
US10675338B1 (en)	2020-06-09
US20180303920A1 (en)	2018-10-25
US20180303919A1 (en)	2018-10-25
US10143732B2 (en)	2018-12-04
US12226466B2 (en)	2025-02-18
IL258599A (en)	2018-06-28
US20190060431A1 (en)	2019-02-28
PH12018500864A1 (en)	2018-10-29
ZA201801036B (en)	2018-12-19
CL2018001531A1 (en)	2018-07-13

Publication	Publication Date	Title
ZA201801036B (en)	2018-12-19	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202005950XA (en)	2020-07-29	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
ZA201800513B (en)	2018-12-19	Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201511792D0 (en)	2015-08-19	Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
ZA201707942B (en)	2018-11-28	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202001665QA (en)	2020-04-29	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202101368WA (en)	2021-03-30	Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201801344SA (en)	2018-04-27	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG11201706155XA (en)	2017-09-28	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
ZA201707810B (en)	2018-11-28	Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
ZA201800129B (en)	2018-12-19	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201604458D0 (en)	2016-04-27	Peptides and combination of peptides for use in immunotherapy against cancers
GB201505305D0 (en)	2015-05-13	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201604490D0 (en)	2016-04-27	Peptides combination of peptides for use in immunotherapy against cancers
IL254129A0 (en)	2017-10-31	Novel peptides and combination of peptides for use in immunotherapy against various tumors
IL254081B (en)	2022-06-01	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
ZA201801013B (en)	2019-02-27	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers